文献速递急性肾损伤

流感疫苗接种与急性肾损伤的关联:前瞻性目标试验模拟研究

Association of Influenza Vaccination With Acute Kidney Injury: A Prospective Target Trial Emulation Study.
PubMed 文献 · Am J Kidney Dis · 2025-10-17

本研究基于英国生物银行65岁及以上人群,采用序贯目标试验模拟设计,评估流感疫苗接种与急性肾损伤(AKI)风险的关联。经倾向评分匹配后纳入97,663对个体,随访1年发现疫苗接种与AKI风险降低17%相关(HR 0.83,95%CI 0.71-0.98),且全因死亡率亦降低(HR 0.75,95%CI 0.66-0.85)。结论支持老年人接种流感疫苗以减少流感及其肾脏相关并发症。

要点

  • 在65岁及以上人群中,流感疫苗接种与1年内AKI风险降低17%独立相关。
  • 疫苗接种组全因死亡率亦显著低于未接种组(HR 0.75,95%CI 0.66-0.85)。
  • 亚组和敏感性分析结果一致,支持老年人接种流感疫苗的肾脏保护作用。

核心结论

  • 在65岁及以上英国生物银行人群中,流感疫苗接种与1年内新发AKI风险显著降低相关(HR 0.83,95%CI 0.71-0.98)。
  • 疫苗接种亦与全因死亡率降低相关(HR 0.75,95%CI 0.66-0.85)。
  • 结果支持在老年人群中推广流感疫苗接种以降低流感及肾脏相关并发症。

研究设计与样本

  • 研究对象为英国生物银行65岁及以上参与者,共1,408,922人-试验(person-trials)纳入全科医疗数据。
  • 经1:1倾向评分匹配后,纳入97,663对个体-试验进行分析。

主要发现

  • 随访1年内共观察到598例新发AKI事件。
  • 未接种组AKI发病率为36.8/10,000人年,接种组为30.6/10,000人年。
  • 倾向评分匹配后,流感疫苗接种与AKI风险降低17%相关(HR 0.83,95%CI 0.71-0.98)。
  • 未接种组累积死亡率为62.8/10,000人年,接种组为47.2/10,000人年,对应HR 0.75(95%CI 0.66-0.85)。
  • 亚组和敏感性分析结果保持一致。

临床怎么用

  • 对于65岁及以上老年人,可考虑将流感疫苗接种作为降低AKI风险的预防措施之一。
  • 临床决策时应结合患者个体情况,权衡疫苗接种的获益与潜在风险。

局限性

  • 疫苗配方和批次差异可能导致残余混杂。
  • 仅纳入英国生物银行中有链接全科医疗数据的参与者,可能存在选择偏倚。
  • 使用基于编码的算法识别AKI,可能存在结局错分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: The impact of influenza vaccination on the risk of acute kidney injury (AKI) has not been thoroughly evaluated in large-scale prospective studies. We assessed whether influenza vaccination was associated with a reduced incidence of AKI among individuals aged 65 years or older. STUDY DESIGN: Target trial emulated with a sequential trial design. SETTING & PARTICIPANTS: Participants aged 65 years or older in the UK Biobank. EXPOSURE: Influenza vaccination compared with no influenza vaccine. OUTCOME: Incident AKI during 1 year after vaccination. Participants were followed from baseline until the diagnosis of AKI, death, loss to follow-up, or for 1 year after entering the study, whichever occurred first. ANALYTICAL APPROACH: Fifty trials were emulated, each with a 1-month enrollment period. These trials began in September 2007 and continued from September to January of the following year until January 2017. Eligible participants could be included in multiple trials until they no longer met the inclusion criteria. Propensity score matching was applied to match vaccine recipients to unvaccinated individuals in a 1:1 ratio to control for confounders, emulating random assignment. A clustered marginal competing risk model that accounts for the within-pair clustering of outcomes was fit to estimate the hazard ratio, along with the 95% confidence interval, characterizing the association between the use of influenza vaccination and incident AKI. RESULTS: Overall, the cohort included 1,408,922 eligible person-trials in the general practice data. After propensity score matching, 97,663 pairs of person-trials were included. During the 1-year follow-up, a total of 598 incident AKI events were observed. In the primary analysis, the incidence of AKI was 36.8 per 10,000 person-years (PYs) in unvaccinated participants and 30.6 per 10,000 PYs in the vaccinated group. After adjusting for potential confounders using propensity score matching, influenza vaccination was associated with a 17% lower AKI risk (HR, 0.83 [95% CI, 0.71-0.98]). The cumulative mortality rates were 62.8 per 10,000 PYs in the unvaccinated group and 47.2 per 10,000 PYs in the vaccinated group, corresponding to an HR of 0.75 (95% CI, 0.66-0.85). These findings remained consistent in subgroup and sensitivity analyses. LIMITATIONS: Potential residual confounding from variations in vaccine formulations and batch; potential selection bias from restricting to participants with linked primary care data in the UK Biobank; and potential outcome misclassification from use of a code-based algorithm to identify AKI. CONCLUSIONS: In this prospective population-based study of older adults within the UK Biobank, influenza vaccination was significantly associated with a lower risk of incident AKI. These findings support use of influenza vaccination in older adults to reduce influenza and its kidney-related complications. PLAIN-LANGUAGE SUMMARY: Influenza infection can damage multiple systems beyond the respiratory system and cause impairment of kidney function. We hypothesized that influenza vaccination may provide a more extensive protective effect beyond respiratory diseases. However, the impact of influenza vaccination on the risk of acute kidney injury (AKI) has not been sufficiently evaluated. This study investigated the association between influenza vaccination and AKI in older adults represented in the UK Biobank, a large prospective cohort. By emulating a targeted randomized clinical trial in this cohort, we found that influenza vaccination may reduce the risk of AKI by 17%. This effect was partially mediated by a reduction in influenza and pneumonia. These findings support the broader implementation of influenza vaccination to reduce both influenza and kidney-related complications in older adult populations.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Zhuo L, Zhang B, Huang Y, et al. Association of Influenza Vaccination With Acute Kidney Injury: A Prospective Target Trial Emulation Study. Am J Kidney Dis. 2025. PMID: 41110628. doi:10.1053/j.ajkd.2025.09.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。